Free shipping on all orders over $ 500

AT-13148

Cat. No. M4806
AT-13148 Structure
Size Price Availability Quantity
10mM*1mL in DMSO USD 155  USD155 In stock
5mg USD 145  USD145 In stock
10mg USD 245  USD245 In stock
50mg USD 645  USD645 In stock
100mg USD 940  USD940 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects in vitro and in vivo. Antitumor efficacy in HER2-positive, PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer, and PTEN-deficient MES-SA uterine tumor xenografts was shown.Induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step.AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell-cycle genes.

Chemical Information
Molecular Weight 313.78
Formula C17H16ClN3O
CAS Number 1056901-62-2
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yap TA, et al. Clin Cancer Res. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.

Related Akt Products
LY2780301

LY2780301 is an oral dual-target inhibitor of AKT/RSK that binds to and inhibits the activity of Akt, thereby inhibiting the PI3K/Akt signaling pathway, which in turn inhibits cell proliferation and induces apoptosis in tumor cells, and possesses antitumor activity.

Akt/SKG Substrate Peptide

Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1.

Adropin (34-76) (human, mouse, rat)

Adropin (34-76) (human, mouse, rat) regulates fuel selection preferences in skeletal muscle.

Apoptin-derived peptide

Apoptin-derived peptide is an antitumor polypeptide with cytotoxicity.

TAT-TCL1-Akt-in

TAT-TCL1-Akt-in is an Akt inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: AT-13148 supplier, Akt, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.